The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction

Pharmacotherapy

Volumn 20, Issue 3, 2000, Pages 318-329

  Swan, Suzanne K ^a   Hursting, Marcie J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESEARCH; FEMALE; HUMAN; HUMAN EXPERIMENT; KIDNEY DISEASE; LIVER DYSFUNCTION; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDY; SEX DIFFERENCE;

EID: 0034049121     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.4.318.34881     Document Type: Article

References (11)

1. 2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]-2- piperidinecarboxylic acid. Biochemistry 1984;23:85-90.
2. Banner DW, Hadváry P. Crystallographic analysis at 3.0-Å resolution of the binding to human thrombin of four active site-directed inhibitors. J Biol Chem 1991;266(30): 20085-93.
3. Lewis BE, Iaffaldano R, McKiernan TL, Rao L, Donkin J, Wallenga JM. Report of successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Cathet Cardiovasc Diagn 1996;38: 206-9.
4. Benet LZ, Mitchell JR, Sheiner LB. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. Elmsford, NY: Pergamon Press, 1990:3-32.
5. Vanholder R, Camez A, Veys N, Van Loo A, Dhondt AM, Ringoir S. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost 1997;77(4):650-5
6. Lefèvre G, Duval M, Gauron S, et al. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clin Pharmacol Ther 1997;62(1):50-9.
7. Warkentin TE. Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management. Drug Saf 1997;17(5):325-41.
8. Izawa O, Katsuki M, Komatsu T, Iida S. Pharmacokinetic studies of argipidine (MD-805) in human - concentrations of argipidine and its metabolites in plasma, urine and feces during and after drip intravenous infusion. Jpn Pharmacol Ther 1986;14(suppl 5):251-63.
9. Tran JQ, Di Cicco RA, Sheth SB, et al. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol 1999;39(5):513-19.
10. Hursting MJ, Joffrion JL, Brooks RL, Swan SK. A comparison of the pharmacodynamics of heparin and argatroban (a direct thrombin inhibitor) in healthy volunteers [abstr]. Blood 1996;88(suppl 1):167a.
11. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60(8):646-9.